Evidence map›Paper›PMID 40702012›Full record

ArticleNPJ vaccines2025

Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.

Rebecca K McLean, Miriam Pedrera, Nazia Thakur, Ahmed M E Elrefaey, Sophia Hodgson, Sue Lowther, Tristan Reid, Shawn Todd, Brenton Rowe, Jemma Bergfeld and 33 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Comprehensive mapping of human CD4Cell reports. Medicine · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Rebecca K McLeanThe Pirbright Institute, Pirbright, UK.
Miriam PedreraThe Pirbright Institute, Pirbright, UK.
Nazia ThakurThe Pirbright Institute, Pirbright, UK.
Ahmed M E ElrefaeyThe Pirbright Institute, Pirbright, UK.
Sophia HodgsonThe Pirbright Institute, Pirbright, UK.
Sue LowtherAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Tristan ReidAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Shawn ToddAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Brenton RoweAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Jemma BergfeldAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Lee TrinidadAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Sarah RiddellAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Sarah EdwardsAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Jean PayneAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Jennifer BarrAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Nick RyeAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Matt BruceAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Tim PooleAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Sheree BrownAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Toni DalzielAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Gough AuAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Megan FisherAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Rachel LaytonAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Teresa LambeJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Keith ChappellSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia.
Ariel IsaacsSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia.
Daniel WattersonSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia.
Mercedes MourinoZoetis Manufacturing & Research Spain S.L, Girona, Spain.
Ruediger RaueZoetis, Zaventem, Belgium.
Ireen Sultana ShantaInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Ayesha SiddikaInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Mst Noorjahan BegumInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Sezanur RahmanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Abdulla Al Mamun BhuyanDepartment of Veterinary & Animal Sciences, University of Rajshahi, Rajshahi, Bangladesh.
Muntasir AlamInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Mohammed Ziaur RahmanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Mustafizur RahmanInfectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Elma TchilianThe Pirbright Institute, Pirbright, UK.
Sarah C GilbertJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Paul YoungSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD, Australia.
Dalan BaileyThe Pirbright Institute, Pirbright, UK.
Glenn A MarshAustralian Centre for Disease Preparedness, Geelong, VIC, Australia.
Simon P GrahamThe Pirbright Institute, Pirbright, UK. simon.graham@pirbright.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007039Biotechnology and Biological Sciences Research Council,United Kingdom BBS/E/I/00007031Innovate UK,United Kingdom 971555
6 · The paper itself

Abstract

Nipah virus (NiV) causes a severe neurological disease in humans. The first NiV outbreak, in Malaysia, involved pig-to-human transmission, that resulted in significant economic losses to the local pig industry. Despite the risk NiV poses to pig-dense regions, no licensed vaccines exist. This study therefore assessed three NiV vaccine candidates in pigs: (1) adjuvanted soluble NiV (s)G protein, (2) adjuvanted pre-fusion stabilised NiV (mcs)F protein, and (3) adenoviral vectored NiV G (ChAdOx1 NiV G). NiV sG induced the strongest neutralising antibody response, NiV mcsF induced antibodies best able to neutralise cell-cell fusion, whereas ChAdOx1 NiV G elicited CD8

Identifiers

PMID40702012
PMCPMC12287429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.